WELLINGTON MANAGEMENT CO LLP 13D and 13G filings for Akero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-08 10:52 am Purchase |
2024-09-30 | 13G | Akero Therapeutics, Inc. AKRO |
WELLINGTON MANAGEMENT CO LLP | 7,896,632 11.370% |
867,008 (+12.33%) |
Filing |
| 2024-09-09 09:09 am Purchase |
2024-08-30 | 13G | Akero Therapeutics, Inc. AKRO |
WELLINGTON MANAGEMENT CO LLP | 7,029,624 10.120% |
4,147,635 (+143.92%) |
Filing |
| 2024-02-08 10:05 am Purchase |
2023-12-29 | 13G | Akero Therapeutics, Inc. AKRO |
WELLINGTON MANAGEMENT CO LLP | 2,881,989 5.170% |
2,005,890 (+228.96%) |
Filing |
| 2023-02-06 2:43 pm Sale |
2022-12-30 | 13G | Akero Therapeutics, Inc. AKRO |
WELLINGTON MANAGEMENT CO LLP | 876,099 1.870% |
-1,000,712 (-53.32%) |
Filing |
| 2022-02-04 09:12 am Purchase |
2021-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
WELLINGTON MANAGEMENT CO LLP | 1,876,811 5.380% |
1,876,811 (New Position) |
Filing |